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Methylation profiling of cancer tissues has identified this mechanism as an important component of carcinogenesis. Epigenetic
silencing of tumour suppressor genes through promoter methylation has been investigated by a variety of means, the most recent of
which is pyrosequencing. We have investigated quantitative methylation status in oral squamous cell carcinoma patients. Fresh
tumour tissue and normal control tissue from resection margin was obtained from 79 consecutive patients undergoing resection of
oral squamous cell carcinoma. DNA was extracted and bisulphite treated. PCR primers were designed to amplify 75–200bp regions
of the CpG rich gene promoters of p16, RARb, E-cadherin, cytoglobin and cyclinA1. Methylation status of 4-5 CpG sites per gene
was determined by pyrosequencing. Significant CpG methylation of gene promoters within tumour specimens was found in 28% for
p16, 73% for RARb, 42% for E-cadherin, 65% for cytoglobin and 53% for cyclinA1. Promoter methylation was significantly elevated in
tumours compared to normal tissue for p16 (P¼0.048), cytoglobin (P¼0.002) and cyclin A1 (P¼0.001) but not in RARb
(P¼0.088) or E-cadherin (P¼0.347). Concordant methylation was demonstrated in this tumour series (P¼0.03). Significant
differences in degree of methylation of individual CpG sites were noted for all genes except RARb and these differences were in a
characteristic pattern that was reproduced between tumour samples. Cyclin A1 promoter methylation showed an inverse trend with
histological grade. Promoter methylation analysis using pyrosequencing reveals valuable quantitative data from several CpG sites. In
contrast to qualitative data generated from methylation specific PCR, our data demonstrated p16 promoter methylation in a highly
tumour specific pattern. Significant tumour specific methylation of cyclin A1 promoter was also seen. Cytoglobin is a novel candidate
tumour suppressor gene highly methylated in upper aero-digestive tract squamous cancer.
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The role of promoter hypermethylation has become a focus for
research in many tumour sites, including head and neck cancer
(HNSCC) (Fan, 2004). Silencing of certain tumour suppressor
genes, central to the development of many solid tumours, may
occur in the absence of genetic change, via aberrant methylation of
CpG islands (Esteller, 2003). Several promising avenues exist in
attempting to translate this research field into the clinical
management of oral squamous cell cancer (OSCC). Attempts to
monitor and prognosticate on the malignant transformation of
oral dysplasia using methylation status have been reported (Kresty
et al, 2002; McGregor et al, 2002; Yeh et al, 2002; Lopez et al, 2003).
Early diagnosis, molecular staging and tumour surveillance of
OSCC have also been explored, with particular emphasis on
minimally invasive methods such as oral rinsing or blood testing
(Sanchez-Cespedes et al, 2000; Ogi et al, 2002). Furthermore,
epigenetic changes, at least in principal, are reversible by
pharmacological means and thus offer potential therapeutic targets
(Coombes et al, 2003).
Published studies have identified a methylation profile or
‘methylotype’ of OSCC by the study of a limited number of genes.
In particular, methylation of the promoters of P14, P15, P16, RASSF1,
MGMT, DAP Kinase, and Sigma 14-3-3 have been well described
(Shaw, 2006). Some genes have been selected by their potential
correlation with clinical behaviour for example, the role of E-cadherin
in cell/cell adhesion and metastasis (Kudo et al, 2004) and of RARb
expression in the prediction of response to chemo-preventative
agents (Wan et al, 1999). Efforts have been made to discover genes
where promoter methylation is specific to, and present in a high
percentage of cases of, malignant tissue and is not found in normal
oral mucosa. These requirements demand well-controlled studies
and, ideally, quantitative methods of methylation analysis. Micro-
array technology and pharmacological reversal of promoter methyla-
tion has lead to the identification of new candidate genes thought to
be epigenetically silenced in HNSCC (Tokumaru et al, 2004), but the
involvement of these genes requires individual verification.
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been described including the use of restriction enzymes (Singer-
Sam et al, 1990), genomic bisulphite sequencing (Frommer et al,
1992) and microarray-based methylation analysis (Huang et al,
1999), however, the overwhelming majority of published data uses
methylation-specific PCR following bisulphite treatment (MSP)
(Herman et al, 1996). MSP has been successfully performed in a
large number of studies providing useful results, mainly due to its
increased sensitivity. However, it yields qualitative rather than
quantitative data and usually evaluates only a few CpG sites at
the 30 end of the primers. It also lacks internal control for adequacy
of bisulphite treatment (all non-50-methylated cytosines should be
fully converted to thymine), making identification of false positives
very difficult. MSP is also potentially liable to oversensitivity
following the high number of PCR cycles sometimes reported, for
example 80 cycles (An et al, 2002). While several methods have
been developed to overcome these shortcomings, pyrosequencing
offers a semiquantitative, high throughput and reliable method
with inbuilt internal control for adequacy of bisulphite treatment
(Colella et al, 2003; Tost et al, 2003; Dupont et al, 2004).
We have evaluated a consecutive series of previously untreated
primary oral cancers using pyrosequencing to quantify promoter
methylation in five genes. The commonly investigated genes, P16,
RARb and E-cadherin (ECAD) were included in this study to allow
comparison with the published MSP literature. We also investi-
gated the promoters of the cyclin A1 (CYCA1) gene, which has
recently been suggested as a promising candidate gene for
epigenetic silencing in HNSCC (Tokumaru et al, 2004), and the
cytoblogin (CYGB) gene, which has been implicated in oesophageal
and lung cancer within our own group (unpublished), but not
previously investigated in OSCC. Quantitative data is presented in
the context of normal controls and also in the light of correlation
with detailed clinical and histopathological data.
MATERIALS AND METHODS
Patients
A total of 79 consecutive patients presenting to the Regional
Maxillofacial Unit, University Hospital Aintree, Liverpool, UK
(www.headandneckcancer.co.uk) with previously untreated squa-
mous cell carcinoma of the oral cavity or oro-pharynx were
consented for tissue collection following appropriate ethical
committee approval. Only those patients undergoing surgery as
the primary treatment were recruited and we estimate that this
includes approximately 90% of all presentations. Demographic,
clinical, pathological and outcome characteristics of each patient
were recorded within the unit’s dedicated head and neck database
(Rogers et al, 1996). Detailed histology data was recorded
(Helliwell and Woolgar, 2005), providing histopathological grading
and staging.
Clinical and pathological characteristics
In all, 52 of the 79 patients were male (66%) with an age range
29–91 years (median 60 years). In all, 45 (57%) were heavy
smokers (420 pack years) and 39 (49%) admitted to alcohol use
428U/week. The commonest sites of tumours were anterior floor
of mouth 20 (25%), oral tongue 18 (23%), tonsil nine (11%) and
maxilla eight (10%). Histopathological assessment following
surgical resection staged the cases as follows: pT1: 14 (18%);
pT2: 30 (38%); pT3: 9 (11%); pT4: 26 (33%). In all, 32 cases (41%)
were pN positive and 21 (27%) had extra-capsular spread.
Tissue collection
Tumour samples 5mm
3 were excised from resected specimens
within the tumour mass, but not involving the margin. Normal
samples of similar dimension were taken from the resection
margin, approximately 10mm from the macroscopic tumour edge
and subsequently confirmed as benign by routine histopathology.
A total of 80 tumour and 25 normal tissue samples were collected
(one patient had synchronous primary tumours), snap frozen in
liquid N2 and subsequently stored at  851C.
DNA extraction and bisulphite treatment
DNA was extracted from 2mm
3 tissue samples using a DNeasyt
tissue kit (Qiagen Ltd). DNA concentration was measured by
spectrophotometry and subsequently adjusted to 40ng/ml. Bisul-
phite treatment of 2mg of each sample was undertaken using the
EZ DNA Methylation Kitt (Zymo Research) and the converted
DNA eluted in 50ml of 0.1 TE buffer. Human genomic DNA
(4mg) was artificially methylated (Matsuo et al, 1994) as a positive
control using SssI (CpG) Methylase (New England Biolabs
s).
Promoter CpG island analysis and primer design
PCR assays were designed to amplify a part of the CpG islands in
the examined gene promoters. Primers targeted CpG-free regions
to ensure that the PCR product would proportionally represent the
methylation characteristics of the source DNA. Pyrosequencing
primers were subsequently designed to focus on a series of four or
five ‘target’ CpG dinucleotides and again avoided CpGs within the
primer sequence (Figure 1). The targeted CpGs were chosen, where
possible (P16, RARb, E-cad) to correlate with those specified by
standard MSP primers previously described. In the case of Cyclin
A1 and CYGB, target regions were selected in line with the
demands of primer design as described.These target CpGs were
evaluated by analysis of the resulting pyrogram. Guanine (or
cytosine if a forward sequencing primer is used) is incorporated
during pyrosequencing if the template CpG was methylated, while
adenine (or thymine) is incorporated if the template CpG was
unmethylated. Thus the proportion of G:A (or C:T) incorporated
is stoichiometrically proportional of the degree of methylation at
that CpG site in the template DNA. The analysis of a non-CpG
cytosine provides an internal control of the completeness of
bisulphite treatment.
Pyrosequencing methylation analysis
Hot-start PCR was carried out with HotStar Taq
s Master Mix Kit
(Qiagen Ltd.) using 3ml bisulphite treated DNA. Confirmation of
PCR product quality and freedom from contamination was
established on 2% agarose gels with ethidium bromide staining.
Pyrosequencing was carried out using the PSQ96MA System
(Biotage) according to manufacturer’s protocol, including single
strand binding protein (PyroGold reagents). PCR primer se-
quences, PCR conditions and sequencing primer sequences are
given in Table 1.
 
Biotin-forward PCR primer
Reverse PCR primer
Pyrosequencing primer
4 x CpG studied
non-CpG cytosine
Figure 1 PCR and sequencing primers for the cytoglobin gene
promoter.
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The methylation index (MtI) at each gene promoter, and for each
sample, was calculated as the average value of
mC/(
mCþC) for all
examined CpGs in the gene.
Statistical correlations between MtI and the clinical variables
recorded were made using SPSS version 11.
RESULTS
Methylation indices
Example bisulphite methylation profiles are shown in Figure 2. The
distribution of methylation indices (MtI) for tumours and normals
is presented in Table 2. There were no tumour samples that had a
zero methylation index for all five genes, however, low-level
methylation (0–5%) was relatively common and we consider this
to represent background ‘noise’ with questionable significance.
The mean MtIs for the positive control DNA (artificially
methylated) were P16: 0.722; RARb: 0.165; CYGB: 0.849;
CYCA1: 0.812; ECAD: 0.702. Tumour MtI was significantly
higher than that of normal tissue in the case of P16, CYGB and
CYCA1 but not RARb or ECAD (Kruskall–Wallis test of mean
rank) (Table 2). This contrast is illustrated by the box and whisker
plots of P16 and ECAD MtI distribution in Figure 3. A total
of 74 of the tumour samples (95%) demonstrated significant
methylation (MtI40.05) at one or more gene promoter.
Pyrosequencing data was successfully generated in 100% of
tested samples for P16, 95% for RARb, 95% for CYGB, 84% for
ECAD and 82% for CYCA1. The internal controls to check for
adequacy of bisulphite treatment, that is methylation of non-CpG
cytosines, suggested 100% of the DNA samples used were
satisfactory in this regard. Samples with failed results were
repeated, where possible by repreparing DNA from the original
tumour specimens, however, this process added little to the
results suggesting that deletions may have been present in the
region of the gene promoter.
Table 1 PCR Primers and conditions
Gene Assay CpG
a Control C Primers
b PCR Conditions
p16  53 Forward PCR AGGGGTTGGTTGGTTATTAG 941C3 0s
 57  51 Reverse PCR Biotin-CTACCTACTCTCCCCCTCTC 941C (14:30m) 581C4 0s  40 cycles 721C (10:00m)
 59 Sequencing (F) GGTTGGTTATTAGAGGGT 721C3 0s
 64
 136
E-Cadherin (CDH1)  144 Forward PCR TTTGATTTTAGGTTTTAGTGAGT 941C3 0s
 150  163 Reverse PCR Biotin-ACCACAACCAATCAACAA 951C (14:30m) 551C3 0s  40 cycles 721C (10:00m)
 158 Sequencing (F) TAGTAATTTTAGGTTAGAGG 721C3 0s
 160
RARb
c 33 Forward PCR Biotin-GTTAAAGGGGGGATTAGAAT 941C3 0s
35 48 Reverse PCR CTCCTTCCAAATAAATACTTACAA 941C (14:30m) 581C4 0s  40 cycles 721C (10:00m)
39 Sequencing (R) ACCCAAACAAACCCT 721C3 0s
44
CyclinA1  589 Forward PCR Biotin-GAGTTAGGGTTTTTAGGA 941C3 0s
 598  596 Reverse PCR CCTCCAACTCCAACTATAC 951C (14:30m) 551C3 0s  40 cycles 721C (10:00m)
 600 Sequencing (R) CTAACAACCCCCTCTA 721C3 0s
 604
Cytoglobin (CYGB)  504 Forward PCR Biotin-GGGAATTGATTTAAAGTTTA 941C3 0s
 507  492 Reverse PCR AAAAAACCCAACTAAATCCAC 951C (14:30m) 521C4 5s  40 cycles 721C (10:00m)
 510 Sequencing (R) ACCCAACTAAATCCAC 721C3 0s
 514
aRelative to transcription start of gene studied.
b(F): sequencing primer extends in the F direction; (R): sequencing primer extends in the R direction.
cExamined CpGs in 50UTR.
180
160
140
120
170
160
150
140
130
120
110
ES T
51 01 5 2 0 2 5
51 01 52 0 2 5
GG G G G G G G AA A A A G A CTC T T T T CC C C
ES TG G G G G G G G AA A A A G A CTC T T T T CC C C
G:0.0%
A:100.0%
G:0.0%
A:100.0%
A:63.0%
G:37.0%
G:35.8%
A:64.2%
G:39.0%
A:61.0%
G:35.7%
A:64.3%
G:0.0%
A:100.0%
G:0.0%
A:100.0%
G:0.0%
A:100.0%
A:100.0%
G:0.0%
MtI=0.000
MtI=0.369
Figure 2 Representative pyrograms for RARb. The four targeted
cytosines are enclosed in unshaded squares (as reverse strand was read,
G peaks (arrowed) indicate methylated cytosine while (A) indicates
unmethylated cytosine). The control, non-CpG cytosine residue showing
complete conversion of cytosine to uracil by bisulphite treatment is shown
in the left-hand shaded box. Normal tissue (top panel) demonstrates no
methylation while tumour tissue (bottom panel) demonstrates a significant
level of methylation at all four target bases. The Methylation Index (MtI) is
calculated as the average rate of G incorporation at each CpG.
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methylation data
There was little evidence of significant correlation between MtI and
the clinical, demographic or pathological data studied. However,
methylation at the CYCA1 gene promoter showed a trend for lower
Anneroth score (Anneroth et al, 1986), a histological grading
system (Spearman’s rank: r¼ 0.253, P¼0.05, but multiple
correlations made this NS). The significance of this is unclear as
no corresponding correlations were found with tumour thick-
ness, lymph node involvement or margin status, any or all of
which might reasonably have been expected to correlate with
histological grade.
Significant correlations, however, were seen between methyla-
tion at RARb and both P16 (r¼0.29, P¼0.01 Spearman’s rank)
and CYGB (r¼0.45, Po0.001). Weaker correlations were seen
between methylation at ECAD and CYCA1 (r¼0.24, P¼0.04),
ECAD and CYGB (r¼ 0.22, P¼0.07), and between P16 and
CYGB (r¼0.19, P¼0.10). This apparent interdependence of
promoter methylation of genes, recently described as ‘concordant
methylation’ (An et al, 2005), was subsequently confirmed by
goodness of fit testing (w
2:12.8 with 5 df, P¼0.03 using
methylation rates 45% for each gene to derive the expected
number of genes with methylation if independent). The number of
cases with significant methylation (MtI40.05) at four or five of the
genes studied was higher than would be expected (by a ratio of
2.1:1) if methylation was an unrelated or random event.
For each gene, the percentage of methylation at each individual
CpG varied in a characteristic pattern that was reproduced
between tumour samples. This is best illustrated by ECAD
promoter methylation (Figure 4). Similar but less exaggerated
patterns were also seen in the other genes and, in all except RARb,
the differences in methylation of different CpGs were significant
(Friedman’s test: P16, ECAD, CYGB, CYCA1: Po0.001; RARb
P¼0.129). These patterns of methylation were also observed in the
positive control DNA prepared using DNA methylase.
DISCUSSION
In this study, we have used pyrosequencing to determine the
methylation profile of oral squamous cell carcinoma in a semi-
quantitative manner. Our data demonstrates tumour-specific
promoter methylation is found in a significant proportion of cases
at P16, CYGB and CYCA1, while methylation of the promoters of
ECAD and RARb was also seen in surrounding normal tissues.
Patterns of concordant methylation have also been demonstrated.
p16 (INK4a) inhibits G1 to S phase passage by binding cyclin
dependent kinase and preventing formation of its complex
with cyclin D. Promoter methylation at P16 has been widely
investigated and reported in the literature. Rates of methylation of
this promoter in OSCC vary between 31% (Maruya et al, 2004) and
67% (Kulkarni and Saranath, 2004). Much of this MSP based
literature has also found high levels in surrounding normal tissue
(50%) (Kulkarni and Saranath, 2004), dysplastic tissue (33%)
(Maruya et al, 2004) and leukoplakia 44% (Lopez et al, 2003)
leading to P16 methylation being previously described as an early
change in oral carcinogenesis of little prognostic value. Using
pyrosequencing, we found that significant methylation was found
in 28% of tumours but in only 4% of the normal tissues. Our
‘normal’ specimens were taken from the surgical resection margin
and whilst frankly involved mucosal margins are uncommon in
this institution (Woolgar and Triantafyllou, 2005), there would
undoubtedly be a significant rate of dysplasia and molecular field
change within these tissues. Drinking and smoking habits,
prevalent in this population, might also be expected to induce
widespread field change in the upper aero-digestive tract
(El Naggar et al, 1995; Scully et al, 2000) Our finding that P16
promoter methylation was highly tumour specific contrasts with
previous published work using MSP and leads us to consider the
benefits of a quantitative rather than qualitative methylation
assay. Pyrosequencing analysis of biopsy material from non-cancer
patients and also from dysplastic keratosis would clearly be of
interest.
Interest in RARb promoter methylation has developed from
studies investigating the potential chemo-preventative role of
retinoids in OSCC (McGregor et al, 2002; Youssef et al, 2004a). The
effects of retinoids are though to be mediated via nuclear receptors
including RARb (Wan et al, 1999). MSP based studies have found
67% of tumours to show methylation of this gene promoter
(Youssef et al, 2004b), and for this methylation to be significantly
higher than normal surrounding tissues. Our pyrosequencing data
shows significant methylation (MtI40.05) in 73% of tumour
samples, however, the trend for higher MtI in tumour than normal
specimens did not reach significance (P¼0.088). In our data, 62%
of the normal specimens had MtI40.05 and this appears to
support existing theories that promoter methylation of RARb is
widespread in apparently normal tissues as well as tumour and is,
perhaps, an early event in carcinogenesis.
Epigenetic silencing of ECAD has been investigated in several
studies and rates of approximately 50% in OSCC are reported
(Chang et al, 2002; Hasegawa et al, 2002; Yeh et al, 2002;
Viswanathan et al, 2003; Maruya et al, 2004). E-cadherin is a
transmembrane glycoprotein responsible for cell–cell adhesion,
the reduced expression of which has been correlated with regional
metastasis in OSCC. While some studies have found a correlation
with promoter methylation and propensity to metastasise (Chang
et al, 2002), this finding is not undisputed (Yeh et al, 2002) and the
relationship between promoter methylation and expression
Table 2 Methylation data and analysis
Gene Samples
% samples
MtI40
a
% samples
MtI45%
b
Kruskall–Wallis test
of mean rank (diff. T/N) Reference MtI
c
% tumours X
Reference MtI
P16 T 45% (36/80) 28% (22/80) P¼0.048 0.046 22/80 28%
N 27% (7/26) 4% (1/26)
RARb T 85% (68/80) 73% (58/80) P¼0.088 (NS) 0.215 15/80 19%
N 71% (15/21) 62% (13/21)
CYGB T 74% (59/80) 65% (52/80) P¼0.002 0.149 35/80 44%
N 57% (12/21) 52% (11/21)
CYCA1 T 72% (56/78) 53% (42/78) P¼0.001 0.002 38/78 49%
N 11% (1/9) 0% (0/9)
ECAD T 83% (59/71) 42% (30/71) P¼0.347 (NS) 0.218 1/71 1%
N 56% (10/18) 33% (6/18)
aMtI¼Methylation index (mean of % methylation at all CpGs/100).
b0–5% methylation is considered to be due to experimental background.
cMtI below which 95% of normal
sample data fall.
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sappears less clear than in other tumour suppressor genes. Our data
suggests that ECAD promoter methylation is the least tumour
specific of the five genes under investigation (P¼0.347). An
MtI40.05 was present in 33% of normal tissues and indeed some
of the highest MtIs for this gene were seen in normal tissues.
Notably, no correlation was found between ECAD MtI and
metastatic potential as determined by pN stage, number of
involved nodes or extra-capsular spread. This contrasts with
previous data implicating this protein in metastasis.
Cyclin A1 is a tissue-specifically expressed gene which is
strongly methylated in solid tumours (Muller-Tidow et al, 2001).
A recent study using demethylation unmasking of potentially
epigenetically silenced genes in HNSCC found that the CYCA1
promoter was methylated in 45% of tumours but in none of the
normal tissues (Tokumaru et al, 2004). Cyclin A1 is involved in
apoptosis and growth arrest downstream of p53; interestingly
the above study found an inverse correlation between CYCA1
promoter methylation and the presence of P53 mutations. The
26 80 N =
Normals Tumours
p
1
6
 
M
e
t
h
 
I
n
x
60
50
40
30
20
10
0
21 80 N =
Normals Tumours
R
A
R
B
4
 
M
e
t
h
 
I
n
d
x
60
50
40
30
20
10
0
21 80 N =
Normals Tumours
C
Y
G
B
 
M
e
t
h
 
I
n
d
x
60
50
40
30
20
10
0
18 71 N =
Normals Tumours
E
C
A
D
 
M
e
t
h
 
I
N
d
x
40
30
20
10
0
9 78 N =
Normals Tumours
C
Y
C
A
1
 
M
e
t
h
 
I
n
d
x
60
50
40
30
20
10
0
Figure 3 Box and whisker plots of methylation Indices for the five genes studied. Boxes include 50% data, O¼Outlier ‘cases with values between 1.5 and
3 box lengths from the upper or lower edge of the box. The box length is the interquartile range.’ *¼Extreme ‘cases with values more than three box
lengths from the upper or lower edge of the box’.
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spyrosequencing data in our study also found methylation status to
be highly tumour specific (P¼0.001) with 53% of tumours having
an MtI40.05. Interestingly our data showed a significant inverse
trend between CYCA1 MtI and Anneroth score, however, this was
in the absence of significant correlations with individual measures
of histological grade and the statistical significance was borderline.
P53 mutations are present in around 50% of OSCC tumours and
have been shown in some studies to correlate with poor prognosis
and radio-resistance (Schliephake, 2003; Yamazaki et al, 2003). It
will be interesting to obtain outcome data for our cohort and
determine whether those with CYCA1 Promoter methylation have
better prognosis.
CYGB is a candidate tumour-suppressor gene on chromosome
17q and is the only gene completely contained within the 42.5kb
Tylosis with Oesophageal Cancer minimal region (Risk et al, 2002).
This region is subject to frequent deletions in sporadic oesopha-
geal cancer, however, no coding mutations have been demon-
strated in affected tylosis patients or a series of squamous
oesophageal tumours (Langan et al, 2004; Shahabi et al, 2004).
Cytoglobin is a recently described, intracellular globin (Burmester
et al, 2002; Burmester et al, 2004) whose role in cancer is as yet
unclear but may be related to detoxification of oxygen free radicals
(Trent, III and Hargrove, 2002). Promoter methylation of CYGB in
lung cancer has recently become the focus of investigation within
our research group and may be implicated in ovarian cancer
(Presneau et al, 2005). The CYGB promoter was found to be
significantly methylated in 46% of lung tumour specimens and
significantly fewer normal controls. Further the MtI of CYGB in
lung tumours correlated with RNA expression (P¼0.001) (un-
published). In OSCC, we now find that the CYGB promoter is
significantly methylated in 65% of tumours and, further, that
methylation is highly tumour specific (P¼0.002). Recently
presented pilot micro-array data also reveals that CYGB is
consistently downregulated in head and neck cancer (Thurlow
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Figure 4 CpG methylation patterns within the promoter regions of the five genes studied.
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set al, 2005). The epigenetic data presented in this study adds
weight to the hypothesis that CYGB is a tumour suppressor gene
highly methylated in upper aero-digestive tract squamous cancer.
The pattern of variable CpG methylation seen within gene
promoters is a new finding made possible by the highly detailed
data generated from pyrosequencing. Explanations underlying
these methylation patterns, as seen in Figure 4, are currently a
matter for speculation. It is possible that these changes result from
experimental artefact, but there is an observable trend towards
lower methylation at any CpG located only a few nucleotides away
from a CpG with high methylation. It may be that steric hindrance
of DNA methylase does not allow equally high methylation of two
closely adjacent CpGs (personal communication: Dr Jorg Tost,
Centre National de Genotypage, Evry, France and Professor Ralph
Krahe, MD Anderson Cancer Centre, TX, USA). Full explanation of
these apparent subtleties, however, awaits further investigation.
Our finding is that these patterns of CpG methylation are
characteristic in any one gene promoter and highly reproducible
between samples. We believe this adds weight to our use of
methylation index in analysis, rather than concentrating on an
individual single CpG site.
The inter-relationship between promoter methylation at several
genes (or ‘concordant methylation’) is worthy of further discus-
sion. The number of cases with significant methylation
(MtI40.05) at four or five of the genes studied was higher than
would be expected (21 vs 10) if methylation was a random event.
This finding suggests the possibility that there is a subgroup of
tumours that may have a predominant epigenetic pathogenesis.
Other subgroups may have principally genetic pathogenesis with
deletions and mutations being more prevalent than promoter
methylation. This hypothesis would need to be tested by
examining a wide range of both genetic and epigenetic aberrations
within the same cohort. The pathological significance of this CpG
island methylation phenotype (CIMP) (Issa, 2004) recently
described in other tumour sites was not seen in this series. This
aspect, however, may be worthy of further investigation when
clinical outcome data from our series become available and as
further genes are studied. We feel that the quantitative data
generated as we describe will add valuable insight to explore this
concept.
In conclusion, we have used pyrosequencing technology to
uncover further details of the epigenetic profile of oral squamous
cell cancer. Our data indicate that P16 promoter methylation is
highly tumour specific, in contrast to some previously published
MSP data, whilst CYCA1 promoter methylation has not previously
been investigated in an oral cancer series and also appears to be
tumour specific. The role of CYGB as a tumour suppressor gene in
oral cancer is also novel and awaits further investigation.
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